Seamus Fernandez
Stock Analyst at Guggenheim
(4.71)
# 148
Out of 5,154 analysts
121
Total ratings
62.5%
Success rate
29.66%
Average return
Main Sectors:
Stocks Rated by Seamus Fernandez
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARQT Arcutis Biotherapeutics | Maintains: Buy | $34 → $35 | $24.00 | +45.83% | 4 | Feb 27, 2026 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $140 → $143 | $93.52 | +52.91% | 4 | Feb 27, 2026 | |
| BMY Bristol-Myers Squibb Company | Maintains: Buy | $62 → $72 | $60.29 | +19.42% | 14 | Feb 6, 2026 | |
| SGMT Sagimet Biosciences | Initiates: Buy | $27 | $5.41 | +399.08% | 1 | Feb 3, 2026 | |
| PCVX Vaxcyte | Reiterates: Buy | $116 | $59.29 | +95.65% | 5 | Feb 2, 2026 | |
| LLY Eli Lilly and Company | Maintains: Buy | $1,163 → $1,161 | $990.33 | +17.23% | 23 | Jan 20, 2026 | |
| GPCR Structure Therapeutics | Maintains: Buy | $90 → $140 | $57.73 | +142.51% | 3 | Jan 20, 2026 | |
| MBX MBX Biosciences | Maintains: Buy | $77 → $88 | $30.55 | +188.05% | 5 | Jan 16, 2026 | |
| TENX Tenax Therapeutics | Maintains: Buy | $14 → $25 | $10.69 | +133.86% | 3 | Dec 17, 2025 | |
| SNY Sanofi | Downgrades: Neutral | n/a | $44.55 | - | 1 | Dec 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $11 | $6.13 | +79.45% | 1 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $7.11 | - | 4 | Oct 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $17 → $25 | $13.85 | +80.51% | 2 | Sep 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $116 | $73.05 | +58.80% | 8 | Jul 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | n/a | $26.59 | - | 2 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $130 → $122 | $115.79 | +5.36% | 14 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $54.51 | - | 2 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $3.54 | - | 3 | Apr 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $38.58 | - | 2 | May 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $160.12 | - | 6 | Feb 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $7.77 | - | 1 | Feb 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $56 → $54 | $3.06 | +1,664.71% | 1 | Mar 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $60 → $45 | $29.43 | +52.91% | 3 | Mar 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $36 → $38 | $194.22 | -80.43% | 6 | Feb 6, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $35 → $38 | $27.05 | +40.48% | 3 | Jan 31, 2018 |
Arcutis Biotherapeutics
Feb 27, 2026
Maintains: Buy
Price Target: $34 → $35
Current: $24.00
Upside: +45.83%
Rhythm Pharmaceuticals
Feb 27, 2026
Maintains: Buy
Price Target: $140 → $143
Current: $93.52
Upside: +52.91%
Bristol-Myers Squibb Company
Feb 6, 2026
Maintains: Buy
Price Target: $62 → $72
Current: $60.29
Upside: +19.42%
Sagimet Biosciences
Feb 3, 2026
Initiates: Buy
Price Target: $27
Current: $5.41
Upside: +399.08%
Vaxcyte
Feb 2, 2026
Reiterates: Buy
Price Target: $116
Current: $59.29
Upside: +95.65%
Eli Lilly and Company
Jan 20, 2026
Maintains: Buy
Price Target: $1,163 → $1,161
Current: $990.33
Upside: +17.23%
Structure Therapeutics
Jan 20, 2026
Maintains: Buy
Price Target: $90 → $140
Current: $57.73
Upside: +142.51%
MBX Biosciences
Jan 16, 2026
Maintains: Buy
Price Target: $77 → $88
Current: $30.55
Upside: +188.05%
Tenax Therapeutics
Dec 17, 2025
Maintains: Buy
Price Target: $14 → $25
Current: $10.69
Upside: +133.86%
Sanofi
Dec 9, 2025
Downgrades: Neutral
Price Target: n/a
Current: $44.55
Upside: -
Nov 18, 2025
Maintains: Buy
Price Target: $13 → $11
Current: $6.13
Upside: +79.45%
Oct 23, 2025
Downgrades: Neutral
Price Target: n/a
Current: $7.11
Upside: -
Sep 15, 2025
Maintains: Buy
Price Target: $17 → $25
Current: $13.85
Upside: +80.51%
Jul 2, 2025
Reiterates: Buy
Price Target: $116
Current: $73.05
Upside: +58.80%
Feb 24, 2025
Reiterates: Buy
Price Target: n/a
Current: $26.59
Upside: -
Jan 17, 2025
Maintains: Buy
Price Target: $130 → $122
Current: $115.79
Upside: +5.36%
Oct 31, 2024
Downgrades: Neutral
Price Target: n/a
Current: $54.51
Upside: -
Apr 29, 2024
Downgrades: Neutral
Price Target: n/a
Current: $3.54
Upside: -
May 31, 2022
Upgrades: Buy
Price Target: n/a
Current: $38.58
Upside: -
Feb 25, 2020
Downgrades: Neutral
Price Target: n/a
Current: $160.12
Upside: -
Feb 3, 2020
Downgrades: Neutral
Price Target: n/a
Current: $7.77
Upside: -
Mar 13, 2018
Maintains: Outperform
Price Target: $56 → $54
Current: $3.06
Upside: +1,664.71%
Mar 8, 2018
Maintains: Market Perform
Price Target: $60 → $45
Current: $29.43
Upside: +52.91%
Feb 6, 2018
Maintains: Market Perform
Price Target: $36 → $38
Current: $194.22
Upside: -80.43%
Jan 31, 2018
Maintains: Market Perform
Price Target: $35 → $38
Current: $27.05
Upside: +40.48%